Frontlight ResearchEarly access
Taking peoplePhase 3
OLE Study With Filgotinib in JIA
Key facts
- Who runs it
- Alfasigma S.p.A.
- Where
- Belgium, Czechia, France, Germany, Greece, Hungary, Italy, Poland, Spain, and United Kingdom39 sites in 10 countriesChoose a country to see its sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 80 people, planned
- Started
- 20 Apr 2026
- Expected to end
- Dec 2027
- Type of study
- Interventional
- Treatments tested
- Filgotinib
- Record updated
- 10 August 2026
Who can take part
- Age
- 8 years to 18 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Subject must have completed treatment with filgotinib in at least one parent study and achieved a clinical benefit at the end of the parent protocols
- Subject and/or parent/legal guardian must be able and willing to comply with the clinical study protocol requirements and must sign and date the informed consent form and assent (if required per local regulation) as approved by the Independent Ethics Committee/ Institutional Review Board, prior to any protocol evaluations
- Female or male subject 8 to <18 years of age, on the date of signing the informed consent and assent (per local regulation) form
- Female subject of childbearing potential who is sexually active and at risk for pregnancy must agree to use contraception/preventive exposure measures as described in the clinical study protocol
Who cannot take part
- Development of any condition during the parent study that would preclude safe continuation
- Active infection that is clinically significant, as per Investigator's judgement
- Subject with known hypersensitivity to the components of potential study therapy
- Subjects with any condition or circumstances (including abnormalities in laboratory parameters) that, in the opinion of the investigator, may make a subject unlikely or unable to complete the study or comply with study procedures and requirements
- Pregnancy
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 8 and 18 years old?
This trial has no sites in United States.
It has sites in 10 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
This OLE study is designed to evaluate long-term safety, tolerability, and efficacy of filgotinib in patients with polyarticular or systemic juvenile idiopathic arthritis (pJIA-sJIA) who have completed the treatment period/prolonged treatment period of the parent studies and demonstrated clinical benefit defined as control of disease activity through improvement in signs and symptoms as per Investigator judgement.
The group in the trial
- FilgotinibTreatment being tested
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- Open-label Extension (OLE), Multiple Dose Study to Evaluate Safety, Tolerability, and Efficacy of Filgotinib in Children and Adolescents From 8 Years to Less Than 18 Years of Age With Juvenile Idiopathic Arthritis (JIA)
- Fit questions
- Built from NCT07553182, who can take part
- Record updated
- 10 August 2026